Conditions: Acute Myelogenous Leukemia Lymphoid Leukemia Chronic Myelogenous Leukemia Malignant Lymphoma Hodgkin's Disease Chronic Lymphocytic Leukemia Myeloproliferative Disorder Anemia, Aplastic Myelodysplastic Syndromes
Keywords: Relapsed or refractory acute myelogenous or lymphoid leukemia. Acute myeloid or lymphocytic leukemia in first remission at high-risk for recurrence.Chronic myelogenous leukemia in accelerated phase or blast-crisis. Chronic myelogenous leukemia in chronic phase Chronic myelogenous leukemia in accelerated phase or blast-crisis Recurrent or refractory malignant lymphoma or Hodgkin's disease. Chronic lymphocytic leukemia, relapsed or with poor prognostic features. Myeloproliferative disorder (polycythemia vera, myelofibrosis) with poor prognostic features. Severe aplastic anemia after failure of immunosuppressive therapy. Myelodysplastic syndromes (including PNH) Multiple myeloma at high risk for disease recurrence.
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 204
Healthy volunteers: no

Brief summary:
Objectives:

1. To evaluate disease free survival after Campath 1H-based in vivo T-cell depletion and non-myelo-ablative ablative stem cell transplantation in patients with hematologic malignancies.
2. To evaluate the incidence and severity of acute and chronic GVHD after Campath 1H-based in vivo T-cell depletion, in patients with hematologic malignancies undergoing non-myelo-ablative stem cell transplantation.
3. To evaluate engraftment and chimerism after Campath 1H-based in vivo T-cell depletion and non-myelo-ablative ablative stem cell transplantation in patients with hematologic malignancies.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Fludarabine intervention 2: Melphalan intervention 3: Stem cells intervention 4: Campath
Intervention descriptions: intervention 1: Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3,. intervention 2: Melphalan 140 mg/m2 IV on day -2. intervention 3: Stem cell infusion on day 0. intervention 4: Campath, 20 mg IV on day -7, 6, -5, -4, and -3.

Protocol document: